Patents by Inventor Dongsheng Duan
Dongsheng Duan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250092386Abstract: The present disclosure is generally directed to an artificial exonic barcode system. The exonic barcodes comprise a nucleotide sequence comprising from 5? to 3? a 5? barcode, an intron, and a 3? barcode, and the disclosure is further directed to a library of these exonic barcodes. The disclosure also describes a method of generating the exonic barcode library and using the library of exonic barcodes in a method of screening for efficiency of transformation and/or expression of one or more genetic constructs in a subject. Primers and probes were also designed for validation of these exonic barcodes and corresponding methods.Type: ApplicationFiled: August 19, 2024Publication date: March 20, 2025Inventors: Dongsheng Duan, Matthew J. Burke, Xiufang Pan, Yongping Yue, Shi-jie Chen, Jun Li
-
Patent number: 12152242Abstract: Disclosed herein are methods for systemically editing a gene in a subject and for systemically treating a genetic condition in a subject using a dual-vector CRISPR-Cas therapy. The methods comprise administering to the subject, via systemic administration, a gene editing AAV vector encoding a CRISPR effector protein (e.g., a Cas protein) and a targeting AAV vector providing one or more gRNAs targeted to the gene. In the methods, the ratio of the targeting AAV vector to the gene editing vector is greater than or equal to 2. Also provided are dual-vector systems for editing a gene or treating a genetic disease in a subject.Type: GrantFiled: April 23, 2019Date of Patent: November 26, 2024Assignees: The Curators of the University of Missouri, The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dongsheng Duan, Chady Hakim, Nalinda B. Wasala, Yongping Yue
-
Publication number: 20240148904Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.Type: ApplicationFiled: November 16, 2023Publication date: May 9, 2024Inventors: Dongsheng Duan, Yi Lai, Junling Zhao, Yongping Yue
-
Publication number: 20230250422Abstract: Disclosed are recombinant adeno-associated virus (rAAV) nucleic acid vectors comprising inverted terminal repeats (ITRs) free of 5?-cytosine-phosphate-guanine-3? (CpG) motifs. Also disclosed are rAAV particles comprising the rAAV vectors, and to compositions and methods for delivering nucleic acids and/or for gene therapy. Further disclosed are compositions and methods for treating diseases with AAV gene therapy using the rAAV vector.Type: ApplicationFiled: April 7, 2021Publication date: August 10, 2023Inventors: DONGSHENG DUAN, XIUFANG PAN, YONGPING YUE
-
Publication number: 20220175964Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.Type: ApplicationFiled: December 17, 2021Publication date: June 9, 2022Inventors: Dongsheng Duan, Yi Lai, Junling Zhao, Yongping Yue
-
Patent number: 11287623Abstract: High-resolution 3D optical polarization tractography (OPT) images of the internal fiber structure of a target tissue. Manipulation of dual-angle imaging data of the fiber orientation inside a target tissue leads to the determination of 3D imaging properties of the target tissue, allowing transmission of the 3D image properties of the target tissue to an OPT processor to produce high-resolution 3D images.Type: GrantFiled: October 10, 2018Date of Patent: March 29, 2022Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Gang Yao, Dongsheng Duan, Yuanbo Wang
-
Patent number: 11202840Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.Type: GrantFiled: June 21, 2017Date of Patent: December 21, 2021Assignee: The Curators of the University of MissouriInventors: Dongsheng Duan, Yi Lai, Junling Zhao, Yongping Yue
-
Publication number: 20210163939Abstract: Disclosed herein are methods for systemically editing a gene in a subject and for systemically treating a genetic condition in a subject using a dual-vector CRISPR-Cas therapy. The methods comprise administering to the subject, via systemic administration, a gene editing AAV vector encoding a CRISPR effector protein (e.g., a Cas protein) and a targeting AAV vector providing one or more gRNAs targeted to the gene. In the methods, the ratio of the targeting AAV vector to the gene editing vector is greater than or equal to 2. Also provided are dual-vector systems for editing a gene or treating a genetic disease in a subject.Type: ApplicationFiled: April 23, 2019Publication date: June 3, 2021Inventors: DONGSHENG DUAN, CHADY HAKIM, NALINDA B. WASALA, YONGPING YUE
-
Publication number: 20210139550Abstract: Disclosed are compositions and methods for treating dystrophinopathies. Compositions include modified dystrophin polynucleotides that encode modified dystrophin proteins having modified hinge 1 (H1) and/or hinge 4 (H4). Also disclosed are methods for treating dystrophinopathies by administering compositions encoding modified dystrophin proteins having modified hinge 1 (H1) and/or modified hinge 4 (H4).Type: ApplicationFiled: April 3, 2019Publication date: May 13, 2021Inventors: Dongsheng DUAN, Lakmini WASALA, Yi LAI, Yongping YUE
-
Patent number: 10351611Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.Type: GrantFiled: April 14, 2017Date of Patent: July 16, 2019Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
-
Publication number: 20190184033Abstract: Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.Type: ApplicationFiled: June 21, 2017Publication date: June 20, 2019Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Dongsheng Duan, Yi Lai, Junling Zhao, Yongping Yue
-
Publication number: 20190041619Abstract: High-resolution 3D optical polarization tractography (OPT) images of the internal fiber structure of a target tissue. Manipulation of dual-angle imaging data of the fiber orientation inside a target tissue leads to the determination of 3D imaging properties of the target tissue, allowing transmission of the 3D image properties of the target tissue to an OPT processor to produce high-resolution 3D images.Type: ApplicationFiled: October 10, 2018Publication date: February 7, 2019Applicant: The Curators of the University of MissouriInventors: Gang Yao, Dongsheng Duan, Yuanbo Wang
-
Patent number: 10133045Abstract: High-resolution 3D optical polarization tractography (OPT) images of the internal fiber structure of a target tissue. Manipulation of dual-angle imaging data of the fiber orientation inside a target tissue leads to the determination of 3D imaging properties of the target tissue, allowing transmission of the 3D image properties of the target tissue to an OPT processor to produce high-resolution 3D images.Type: GrantFiled: July 29, 2016Date of Patent: November 20, 2018Assignee: The Curators of the University of MissouriInventors: Gang Yao, Dongsheng Duan, Yuanbo Wang
-
Publication number: 20170349640Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.Type: ApplicationFiled: April 14, 2017Publication date: December 7, 2017Inventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
-
Patent number: 9624282Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.Type: GrantFiled: November 26, 2013Date of Patent: April 18, 2017Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
-
Publication number: 20170031143Abstract: High-resolution 3D optical polarization tractography (OPT) images of the internal fiber structure of a target tissue. Manipulation of dual-angle imaging data of the fiber orientation inside a target tissue leads to the determination of 3D imaging properties of the target tissue, allowing transmission of the 3D image properties of the target tissue to an OPT processor to produce high-resolution 3D images.Type: ApplicationFiled: July 29, 2016Publication date: February 2, 2017Applicant: The Curators of the University of MissouriInventors: Gang Yao, Dongsheng Duan, Yuanbo Wang
-
Patent number: 8846030Abstract: Agents and methods to alter rAAV transduction are provided.Type: GrantFiled: December 13, 2005Date of Patent: September 30, 2014Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan
-
Publication number: 20140234255Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.Type: ApplicationFiled: November 26, 2013Publication date: August 21, 2014Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
-
Patent number: 7892824Abstract: The present invention provides novel dystrophin mini/micro-genes that retain the essential biological functions of a full-length dystrophin gene. More particularly, the present invention provides to a series of synthetic mini/micro-dystrophin genes capable of restoring neuronal nitric oxide synthase (nNOS) to the sarcolemma. A method as well as a pharmaceutical composition for treatment of Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and X-linked Dilated Cardiomyopathy (XLDC) are also provided.Type: GrantFiled: January 18, 2008Date of Patent: February 22, 2011Assignee: University of Missouri-ColumbiaInventors: Dongsheng Duan, Yi Lai, Yongping Yue
-
Patent number: 7803622Abstract: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.Type: GrantFiled: February 15, 2005Date of Patent: September 28, 2010Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan